DelveInsight’s “TGF Beta Inhibitors Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the TGF Beta Inhibitors pipeline landscape. It covers the TGF Beta Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TGF Beta Inhibitors Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight
Key Takeaways from the TGF Beta Inhibitors Pipeline Report
- In December 2025, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins conducted a study is to compare the progression free survival (PFS) of patients with metastatic castration-resistant prostate cancer treated with enzalutamide in combination with LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).
- In November 2025, ImmunityBio Inc. announced a study involves a Phase 1b dose escalation portion with up to 30 patients to determine the MTD using a 3+3 dose escalation design and to designate a dose level for the Phase 2 expansion phase (RP2D).
- DelveInsight’s TGF Beta Inhibitors Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for TGF Beta Inhibitors treatment.
- The leading TGF Beta Inhibitors Companies such as Acceleron Pharma, Isarna Therapeutics, Forbius and others.
- Promising TGF Beta Inhibitors Therapies such as Enzalutamide, LY2157299, HCW9218, FOLFIRNINOX, Losartan, ES014, Sorafenib and others.
Want to know which companies are leading innovation in TGF Beta Inhibitors? Dive into the full pipeline insights @ TGF Beta Inhibitors Clinical Trials Assessment
The TGF Beta Inhibitors Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The TGF Beta Inhibitors Pipeline Report also highlights the unmet needs with respect to the TGF Beta Inhibitors.
TGF Beta Inhibitors Overview
Transforming growth factor (TGF)-β is a secreted multifunctional cytokine that signals via plasma membrane TGF-β type I and type II receptors and intercellular SMAD transcriptional effectors. Aberrant inter- and intracellular TGF-β signaling can contribute to cancer progression. In normal cells and early stages of cancer, TGF-β can stimulate epithelial growth arrest and elicit a tumor suppressor function. However, in late stages of cancer, when the cytostatic effects of TGF-β in cancer cells are blocked, TGF-β signaling can act as tumor promoter by its ability to stimulate epithelial-to-mesenchymal transition of cancer cells, by stimulating angiogenesis, and by promoting evasion of immune responses.
TGF Beta Inhibitors Emerging Drugs Profile
- Luspatercept – Acceleron Pharma
Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.
If you’re tracking ongoing TGF Beta Inhibitors Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ TGF Beta Inhibitors Treatment Drugs
The TGF Beta Inhibitors Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of TGF Beta Inhibitors with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for TGF Beta Inhibitors Treatment.
- TGF Beta Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- TGF Beta Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the TGF Beta Inhibitors market.
TGF Beta Inhibitors Companies
Acceleron Pharma, Isarna Therapeutics, Forbius and others.
TGF Beta Inhibitors Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
TGF Beta Inhibitors Products have been categorized under various Molecule types such as,
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
From emerging drug candidates to competitive intelligence, the TGF Beta Inhibitors Pipeline Report covers it all – check it out now @ TGF Beta Inhibitors Market Drivers and Barriers, and Future Perspectives
Scope of the TGF Beta Inhibitors Pipeline Report
- Coverage- Global
- TGF Beta Inhibitors Companies- Acceleron Pharma, Isarna Therapeutics, Forbius and others.
- Promising TGF Beta Inhibitors Therapies- Enzalutamide, LY2157299, HCW9218, FOLFIRNINOX, Losartan, ES014, Sorafenib and others.
- TGF Beta Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- TGF Beta Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the TGF Beta Inhibitors Treatment landscape in this detailed analysis @ TGF Beta Inhibitors Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- TGF-Beta Inhibitors: Overview
- Pipeline Therapeutics
- Therapeutics Assessment
- TGF-Beta Inhibitors – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- TGF-Beta Inhibitors Collaboration Deals
- Late Stage Products (Phase III)
- Luspatercept – Acceleron Pharma
- Early Stage Products (Phase I)
- ISTH0036: Isarna Therapeutics
- Pre-clinical and Discovery Stage Products
- ISTH1106: Isarna Therapeutics
- Inactive Products
- TGF-Beta Inhibitors Key Companies
- TGF-Beta Inhibitors Key Products
- TGF-Beta Inhibitors- Unmet Needs
- TGF-Beta Inhibitors- Market Drivers and Barriers
- TGF-Beta Inhibitors- Future Perspectives and Conclusion
- TGF-Beta Inhibitors Analyst Views
- TGF-Beta Inhibitors Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
